AFFINITY THERAPEUTICS
Affinity Therapeutics, LLC was founded to commercialize technology developed at Case Western Reserve University (CWRU). This technology is controlled release of therapeutics using molecular interactions to obtain release rates and durations not available by diffusion alone. By utilizing this platform technology, Affinity is poised to change how therapeutics are delivered in several markets including the advanced wound care and hernia mesh.
AFFINITY THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2010-01-01
Address:
Cleveland, Ohio, United States
Country:
United States
Website Url:
http://www.affinitytherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
2163684969
Email Addresses:
[email protected]
Total Funding:
550 K USD
Technology used in webpage:
Dingfeng Xinhui DXTL Tseung Kawn
Similar Organizations
Forge Therapeutics
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Current Employees Featured
Founder
Investors List
National Science Foundation
National Science Foundation investment in Grant - Affinity Therapeutics
Official Site Inspections
http://www.affinitytherapeutics.com Semrush global rank: 11.61 M Semrush visits lastest month: 155
- Host name: 149.29.117.18
- IP address: 149.29.117.18
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Affinity Therapeutics"
Affinity Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
Affinity Therapeutics is a research-driven biotech company focusing on the design and delivery of life-enhancing medical applications. Industries. Biotechnology, Health Care +1. Headquarters. Cleveland, United States. Stage. Grant. Employees. 1-10. Links. Discover similar companies. …See details»
Affinity Therapeutics Company Profile | Management and
Affinity Therapeutics Profile and History. Established in 2010, Affinity Therapeutics, LLC, is a leading, research-driven bio-tech company focused on the design and delivery of life-enhancing medical applications to advance medical care decisions and outcomes. Designed to meet the …See details»
Affinity Therapeutics, LLC - Company Profile & Staff Directory
Affinity Therapeutics, LLC was founded to commercialize technology developed at Case Western Reserve University (CWRU). This technology is controlled release of therapeutics using molecular interactions to obtain release rates and durations not available by diffusion alone. By utilizing …See details»
Affinity Therapeutics - Overview, News & Similar companies
Affinity Therapeutics contact info: Phone number: (216) 224-9364 Website: www.affinitytherapeutics.com What does Affinity Therapeutics do? Established in 2010, Affinity Therapeutics, LLC, is a leading, research-driven bio-tech company focused on the design and …See details»
Affinity Therapeutics - Craft
Affinity Therapeutics is a research-driven biotech company focused on the design and delivery of life-enhancing medical applications. Its controlled-release, tunable technology is used in a variety of medical fields, such as regenerative medicine, oncology, and advanced wound therapy. …See details»
Affini-T Therapeutics | Unlocking the power of T cells
11.06.2024. Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingSee details»
Affinity Therapeutics - Crunchbase
Affinity Therapeutics is a research-driven biotech company focusing on the design and delivery of life-enhancing medical applications. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Organization. Affinity …See details»
Affinity Therapeutics - Funding, Financials, Valuation & Investors
Affinity Therapeutics is a research-driven biotech company focusing on the design and delivery of life-enhancing medical applications. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Organization. Affinity …See details»
Affinity Therapeutics, LLC - VentureRadar
Affinity Therapeutics, LLC VentureRadar profile. Find out more about Affinity Therapeutics, LLC, Drug Delivery, Drug delivery system and Drug Delivery and Formulation.See details»
Nextsource | Company Profile | Affinity Therapeutics
Find out if Affinity Therapeutics is undergoing leadership changes or executive team restructuring. Get detailed insights into the financial health of Affinity Therapeutics . Track key 'champions' at Affinity Therapeutics as they move through different departments or take on new roles.See details»
Affini-T Therapeutics, Inc. - MassBio
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering, and synthetic biology capabilities to target even the …See details»
Affini-T Therapeutics - LinkedIn
Affini-T Therapeutics | 10,089 followers on LinkedIn. Right Targets. Right Cells. Right Place. Unlocking the power of T cells against oncogenic driver mutations. | Affini-T is a leading clinical ...See details»
Affini-T plans to go public in 2024 - Fierce Biotech
Jul 25, 2023 The IPO window is starting to crack open and Affini-T Therapeutics plans to push through in 2024. The financial plans relayed by CEO Jak Knowles in an interview with Fierce Biotech occur as the ...See details»
Affini-T Therapeutics Named to the 2022 Endpoints 11
Sep 22, 2022 BOSTON & SEATTLE--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has been selected by Endpoints News ...See details»
New insights into protein–protein interaction modulators in drug ...
2 days ago The study of protein-protein interactions (PPIs) has significantly evolved from early observations of protein complexes in biological systems to a deep and complex understanding of the underlying ...See details»
Affini-T Therapeutics Completes $175 Million Financing Co-Led by …
Mar 22, 2022 BOSTON & SEATTLE & LEVERKUSEN, Germany--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the ...See details»
Affini-T Therapeutics Completes $175 Million Financing Co-Led by …
Mar 22, 2022 11.06.2024. Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingSee details»
Affini-T Therapeutics - Crunchbase Company Profile & Funding
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies.See details»
Affini-T Therapeutics to Present Preclinical Data from its …
Apr 6, 2023 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its ChiefSee details»
Affini-T Therapeutics Completes $175 Million Financing Co-Led
Mar 22, 2022 Boston, Mass., and Seattle, Wash., and Leverkusen, Germany, March 22, 2022 - Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the completion of an oversubscribed $175 …See details»